Dr. Katerina Otrubova is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations practice. She assists with the preparation and prosecution of patent applications in the chemistry, pharmaceuticals, and biotechnology fields.
Prior to joining the firm, Katerina was a postdoctoral fellow on the drug discovery team of the Skaggs School of Pharmacy at the University of California, San Diego. In this role, she focused on the screening of chemical libraries and on the design and synthesis of organic small molecules for the treatment of infectious diseases. During her doctoral work at The Scripps Research Institute in La Jolla, California, she developed small molecule inhibitors of fatty acid amide hydrolase, as well as new synthetic methodologies for small molecule libraries.
Katerina is a co-author on 16 peer-reviewed scientific articles and is a co-inventor on one U.S. patent application.
Dr. Katerina Otrubova is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations practice. She assists with the preparation and prosecution of patent applications in the chemistry, pharmaceuticals, and biotechnology fields.
Prior to joining the firm, Katerina was a postdoctoral fellow on the drug discovery team of the Skaggs School of Pharmacy at the University of California, San Diego. In this role, she focused on the screening of chemical libraries and on the design and synthesis of organic small molecules for the treatment of infectious diseases. During her doctoral work at The Scripps Research Institute in La Jolla, California, she developed small molecule inhibitors of fatty acid amide hydrolase, as well as new synthetic methodologies for small molecule libraries.
Katerina is a co-author on 16 peer-reviewed scientific articles and is a co-inventor on one U.S. patent application.
- Ph.D., Organic Chemistry, The Scripps Research Institute (TSRI)
- B.S., Chemistry, University of California, Berkeley
- Member, San Diego Intellectual Property Law Association
- U.S. Patent and Trademark Office
- Ph.D., Organic Chemistry, The Scripps Research Institute (TSRI)
- B.S., Chemistry, University of California, Berkeley
- Member, San Diego Intellectual Property Law Association
- U.S. Patent and Trademark Office
Select Publications
- Co-author with V. Srinivasan and D.L. Boger, "Discovery libraries targeting the major enzyme classes: The serine hydrolases," 24(16) Bioorganic Medicinal Chemistry Letters 3807-13, 2014
- Co-author with K.K. Duncan and D.L. Boger, "Chromane α-ketoheterocycle inhibitors of fatty acid amide hydrolase: An exploration of conformational constraints in the acyl side chain," 22(9) Bioorganic Medicinal Chemistry Letters 2763-70, 2014
- Co-author with B.F. Cravatt and D.L. Boger, "Design, synthesis, and characterization of ?-ketoheterocycles additionally targeting the cytosolic port Cys269 of fatty acid amide hydrolase," 57(3) Journal of Medicinal Chemistry 1079-89, 2014
- Co-author with M. Brown, S.T. O'Neal, R. C. Stevens, B. F. Cravatt, A.H. Lichtman, and D.L. Boger, "Rational design of fatty acid amide hydrolase (FAAH) inhibitors that act by covalently bonding to two active site residues," 135(16) Journal of the American Chemical Society 6289-99, 2013
- Co-author with D.L. Boger, "α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)," 3(5) A.C.S. Chemistry Neurosciences 340-8, 2012
- Co-author with G. Lushington, D. Vander Velde, K.L. McGuire, and S. R. McAlpine, "A comprehensive study of Sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines," 51(3) Journal of Medicinal Chemistry 530-44, 2008
- Co-author with K.L. McGuire and S.R. McAlpine, "Scaffold targeting drug-resistant colon cancers," 50(9) Journal of Medicinal Chemistry 1999-2002, 2007
Select Publications
- Co-author with V. Srinivasan and D.L. Boger, "Discovery libraries targeting the major enzyme classes: The serine hydrolases," 24(16) Bioorganic Medicinal Chemistry Letters 3807-13, 2014
- Co-author with K.K. Duncan and D.L. Boger, "Chromane α-ketoheterocycle inhibitors of fatty acid amide hydrolase: An exploration of conformational constraints in the acyl side chain," 22(9) Bioorganic Medicinal Chemistry Letters 2763-70, 2014
- Co-author with B.F. Cravatt and D.L. Boger, "Design, synthesis, and characterization of ?-ketoheterocycles additionally targeting the cytosolic port Cys269 of fatty acid amide hydrolase," 57(3) Journal of Medicinal Chemistry 1079-89, 2014
- Co-author with M. Brown, S.T. O'Neal, R. C. Stevens, B. F. Cravatt, A.H. Lichtman, and D.L. Boger, "Rational design of fatty acid amide hydrolase (FAAH) inhibitors that act by covalently bonding to two active site residues," 135(16) Journal of the American Chemical Society 6289-99, 2013
- Co-author with D.L. Boger, "α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)," 3(5) A.C.S. Chemistry Neurosciences 340-8, 2012
- Co-author with G. Lushington, D. Vander Velde, K.L. McGuire, and S. R. McAlpine, "A comprehensive study of Sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines," 51(3) Journal of Medicinal Chemistry 530-44, 2008
- Co-author with K.L. McGuire and S.R. McAlpine, "Scaffold targeting drug-resistant colon cancers," 50(9) Journal of Medicinal Chemistry 1999-2002, 2007
Therapeutics and Drug Discovery
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Peptide therapeutics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
- Peptidomimetics
- Polymers
- Polymorph
- Process chemistry
Therapeutics and Drug Discovery
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Peptide therapeutics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
- Peptidomimetics
- Polymers
- Polymorph
- Process chemistry
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
- Privacy Policy
- Terms of Use
- Accessibility